Business
Notice of 2021 Full-Year Results and Annual Report
Notice of 2021 Full-Year Results and Annual Report.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n RNS Number : 7637D\n Faron Pharmaceuticals Oy\n 07 March 2022\n \n \n \n \n Faron Pharmaceuticals Ltd\n \n \n (\"Faron\" or the \"Company\")\n \n \n \n \n \n Notice of 2021 Full-Year Results and Annual Report\n \n \n \n \n \n \n \n \n Press Release, March 7, 2022 at 09:00 AM (EET) / 07:00 AM (GMT) / 02:00 AM (EST) \n \n \n \n \n \n \n \n \n \n TURKU, FINLAND\n \n / BOSTON, MA - \n Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, will publish its audited full-year results for the twelve months ended December 31, 2021 on Friday, March 25, 2022 at 9:00 am EET, 7:00 am GMT, 3:00 am EDT. The Annual Report 2021, including audited financial statements for the full year, will be published on the same day.\n \n \n \n \n \n A virtual briefing and Q&A session for analysts will be hosted by Dr. Markku Jalkanen, Chief Executive Officer of Faron, and Toni Hänninen, Chief Financial Officer of Faron, at 2:00 pm EET / 12:00 pm GMT / 8:00 am EDT on the day of results. The Full-year results release for 2021, presentation, webcast details, and Annual Report 2021 will be made available at \n \n www.faron.com/investors\n \n . A replay of the analyst briefing will be made available shortly afterwards.\n \n \n \n \n \n For more information please contact:\n \n \n \n \n \n Media / Investor Contact\n \n \n Faron Pharmaceuticals\n \n \n Eric Van Zanten\n \n \n Head of Communications\n \n \n \n \n [email protected]\n \n \n \n \n [email protected]\n \n \n Phone: +1 (610) 529-6219\n \n \n \n \n \n Cairn Financial Advisers LLP, Nomad\n \n \n Sandy Jamieson, Jo Turner\n \n \n Phone: +44 (0) 207 213 0880\n \n \n \n \n \n Peel Hunt LLP, Broker\n \n \n Christopher Golden, James Steel\n \n \n Phone: +44 (0) 20 7418 8900\n \n \n \n \n \n Sisu Partners Oy, Certified Adviser on Nasdaq First North\n \n \n Juha Karttunen\n \n \n Phone: +358 (0)40 555 4727\n \n \n Jukka Järvelä\n \n \n Phone: +358 (0)50 553 8990\n \n \n \n \n \n Consilium Strategic Communications\n \n \n Mary-Jane Elliott, David Daley, Lindsey Neville\n \n \n \n \n [email protected]\n \n \n \n ...